2. Search Result
Search Result
Results for "

depletion

" in MedChemExpress (MCE) Product Catalog:

75

Inhibitors & Agonists

1

Fluorescent Dye

5

Biochemical Assay Reagents

3

Peptides

13

Inhibitory Antibodies

7

Natural
Products

7

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W010342
    6-Aminonicotinamide
    4 Publications Verification

    		 Others Cancer
    6-Aminonicotinamide, a potent antimetabolite of nicotinamide, is competitive NADP +-dependent enzyme glucose-6-phosphate dehydrogenase (G6PD) inhibitor (Ki=0.46 μM). 6-Aminonicotinamide resultis ATP depletion and synergizes with DNA-crosslinking chemotherapy agents, such as Cisplatin, in killing cancer cells .
    6-Aminonicotinamide
  • HY-121134
    Decylubiquinone

    		Reactive Oxygen Species Neurological Disease Cancer
    Decylubiquinone is an analog of ubiquinone (coenzyme Q10). Decylubiquinone blocks reactive oxygen species (ROS) production in response to glutathione depletion and inhibits activation of the mitochondrial permeability transition .
    Decylubiquinone
  • HY-145282
    MS170

    		PROTACs Akt Cancer
    MS170 is a potent and selective PROTAC AKT degrader. MS170 depletes cellular total AKT (T-AKT) with the DC50 value of 32 nM. MS170 binds to AKT1, AKT2, and AKT3 with Kds of 1.3 nM, 77 nM, and 6.5 nM, respectively .
    MS170
  • HY-P9948
    Alemtuzumab

    Campath-IH

    		 Apoptosis Cancer
    Alemtuzumab (Campath-IH) is a humanized monoclonal antibody against CD52. Alemtuzumab does not cross-react with murine CD52. Alemtuzumab selectively targets the CD52 antigen to induce profound lymphocyte depletion, followed by recovery of T and B cells with regulatory phenotypes. Alemtuzumab is capable of complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity (ADCC), as well as induction of apoptosis. Alemtuzumab has the potential for B-cell chronic lymphocytic leukaemia research .
    Alemtuzumab
  • HY-145281
    MS98

    		PROTACs Akt Cancer
    MS98 is a potent and selective PROTAC AKT degrader. MS98 depletes cellular total AKT (T-AKT) with the DC50 value of 78 nM. MS98 binds to AKT1, AKT2, and AKT3 with Kds of 4 nM, 140 nM, and 8.1 nM, respectively .
    MS98
  • HY-W018161
    Hexadecanedioic acid

    		Endogenous Metabolite Others
    Hexadecanedioic acid is covalently linked to Sepharose 4B, shows better performance in terms of specificity than dye-based resins and could be used for depletion of SA from plasma samples.
    Hexadecanedioic acid
  • HY-156187
    Anticancer agent 161

    		Others Cancer
    Anticancer agent 161 (Compound 3b) is a bioactive alkynol with anti-cancer potential. Anticancer agent 161 can trigger autophagy and mitochondrial membrane potential depletion .
    Anticancer agent 161
  • HY-P990042
    Gotistobart

    ONC-392; BNT 316

    		 CTLA-4 Cancer
    Gotistobart (ONC-392) is a humanized anti-CTLA-4 antibody that confers immunotherapeutic effect by selective depletion of regulatory T cells (Treg) in the tumor microenvironment .
    Gotistobart
  • HY-19771
    amyloid P-IN-1

    		Amyloid-β Cancer
    amyloid P-IN-1 is used in the research of diseases or disorders wherein depletion of serum amyloid P component (SAP), including amyloidosis, Alzheimer's disease, type 2 diabetes mellitus and osteoarthritis.
    amyloid P-IN-1
  • HY-12504
    Pyr6
    1 Publications Verification

    N-[4-[3,5-Bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-fluoro-4-pyridinecarboxamide

    		 TRP Channel Others
    Pyr6 is a selective inhibitor of TRPC3 with IC50 of 0.49 uM(Ca2+ influx inhibition in thapsigargin depleted native RBL-2H3 cells).
    Pyr6
  • HY-Y1147
    Diethyl maleate

    Maleic acid diethyl ester
    Diethyl maleate is a maleate ester resulting from the formal condensation of both carboxy groups of maleic acid with ethanol. Diethyl maleate (DEM), a thiol-reactive α,β-unsaturated carbonyl compound, depletes glutathione (GSH) in exposed cells .
    Diethyl maleate
  • HY-P99670
    Iscalimab

    CFZ-533; OM11-62MF

    		 TNF Receptor Metabolic Disease Inflammation/Immunology
    Iscalimab (CFZ-533) is a non-depleting IGg1 monoclonal antibody targeting CD40 (KD: 0.3 nM). Iscalimab can be used for research of Graves' hyperthyroidism and autoimmune diseases .
    Iscalimab
  • HY-12628
    GNE-618

    		NAMPT Cancer
    GNE-618 is a potent, orally active nicotinamide phosphoribosyl transferase (NAMPT) inhibitor with an IC50 of 6 nM. GNE-618 depletes NAD levels and induces tumor cell death. Anti-tumor activity .
    GNE-618
  • HY-N12125
    Entadamide A

    		Others Infection
    Entadamide A (compound 1) is a tryptophan derivative. Entadamide A prevents tryptophan depletion by inhibiting indoleamine 2, 3-dioxygenase (IDO), thereby inhibiting HIV replication. Entadamide A can be used in drug and neuropsychiatric studies of redesivir [1].
    Entadamide A
  • HY-W018161S
    Hexadecanedioic acid-d28

    		Endogenous Metabolite Others
    Hexadecanedioic acid-d28 is the deuterium labeled Hexadecanedioic acid. Hexadecanedioic acid is covalently linked to Sepharose 4B, shows better performance in terms of specificity than dye-based resins and could be used for depletion of SA from plasma samples.
    Hexadecanedioic acid-d28
  • HY-151940
    Mal-Pc

    		Reactive Oxygen Species Cancer
    Mal-Pc is a versatile molecular photosensitizer designed based phthalocyanine and maleimides. Mal-Pc can react with GSH to deplete GSH and reduce aggregation, thereby improving ROS (Reactive Oxygen Species)-mediated effect of photodynamic therapy (PDT) in cancer cells .
    Mal-Pc
  • HY-P99904
    Siplizumab

    MEDI-507

    		 CD2 Inflammation/Immunology
    Siplizumab (MEDI-507) is a humanized IgG1 monoclonal antibody against CD2. Siplizumab depletes T cells, decreases T cell activation, inhibites T cell proliferation and enriches naïve and bona fide regulatory T cells .
    Siplizumab
  • HY-139047
    SW157765

    		GLUT Cancer
    SW157765 is a selective non-canonical glucose transporter GLUT8 (SLC2A8) inhibitor. KRAS/KEAP1 double mutant NSCLC cells are selectively sensitive to the SW157765, due to the convergent consequences of dual KRAS and NRF2 modulation of metabolic and xenobiotic gene regulatory programs .
    SW157765
  • HY-P1923
    L-Asparaginase
    5+ Cited Publications

    L-​ASNase

    		 Apoptosis DNA/RNA Synthesis Cancer
    L-Asparaginase (L-ASNase) is a deamidating enzyme that catalyses the hydrolysis of L-asparagine and L-glutamine, and can be used for the research of acute lymphoblastic leukemia. L-Asparaginase depletes L-asparagine from plasma resulting in inhibition of RNA and DNA synthesis with the subsequent blastic cell apoptosis .
    L-Asparaginase
  • HY-103400
    8-Chloroadenosine

    8-Cl-Ado

    		 AMPK Autophagy Cancer
    8-Chloroadenosine (8-Cl-Ado), a unique ribonucleoside analog, depletes endogenous ATP that subsequently induces the phosphorylation and activation of AMPK. 8-Chloroadenosine induces autophagic cell death. 8-Chloroadenosine effectively inhibited in vivo tumor growth in mice .
    8-Chloroadenosine
  • HY-118064
    (R)-Thionisoxetine

    LY-368975

    		 Others Neurological Disease
    (R)-Thionisoxetine is a potent and selective inhibitor of central and peripheral norepinephrine (NE) uptake. (R)-thionisoxetine prevented hypothalamic NE depletion by 6-hydroxydopamine with an ED50 of 0.21 mg/kg. (R)-Thionisoxetine can be used for the research of a variety of diseases including depression and urinary incontinence .
    (R)-Thionisoxetine
  • HY-A0119
    Nitroprusside disodium dihydrate
    4 Publications Verification

    Sodium nitroprusside dihydrate; Sodium Nitroferricyanide(III) Dihydrate

    		 Autophagy Cardiovascular Disease Cancer
    Nitroprusside disodium dehydrate (Sodium nitroprusside dihydrate) is a vasodilator that available for the research of acute hypertension, heart failure. Nitroprusside disodium dehydrate induces autophagy in glutathione-depleted osteoblasts. Nitroprusside disodium dehydrate acts as a nitric oxide (NO) donor in a rat intestinal ischemia reperfusion model .
    Nitroprusside disodium dihydrate
  • HY-P99321
    Teneliximab

    BMS 224819; Chi220; Anti-Human CD40 Recombinant Antibody

    		 TNF Receptor Inflammation/Immunology Cancer
    Teneliximab (BMS-224819) is a chimeric monoclonal antibody, blocks the CD40-CD40L interaction. Teneliximab (BMS-224819) has partial agonist activity resulting in some signaling through CD40 and peripheral B cell depletion .
    Teneliximab
  • HY-P99313
    Quilizumab

    Anti-Human NGcGM3 Recombinant Antibody

    		 Apoptosis Inflammation/Immunology
    Quilizumab (Anti-Human NGcGM3 Recombinant Antibody) is a humanized IgG1κ monoclonal antibody. Quilizumab targets the M1-prime segment of membrane-expressed IgE, leading to depletion of IgE-switched and memory B cells. Quilizumab has the potantial for the asthma research .
    Quilizumab
  • HY-19587
    Ditercalinium chloride

    NSC335153
    Ditercalinium chloride is an anticancer agent. Ditercalinium chloride inhibits human DNA polymerase gamma activity. Ditercalinium chloride can deplete mitochondrial DNA in both mouse and human cells. Ditercalinium chloride is a potential ligand against the COMMD10-AP3S1 fusion protein .
    Ditercalinium chloride
  • HY-N4115
    Syrosingopine
    3 Publications Verification

    Su 3118

    		 Monocarboxylate Transporter Cardiovascular Disease Cancer
    Syrosingopine (Su 3118) is an orally active lactate transporters (MCT1/MCT4) dual inhibitor, which can reduce glycolysis and induce synthetic lethality in cancer cells when combine with metformin. Syrosingopine shows anti-hypertensive activity by depleting peripheral stores of norepinephrine .
    Syrosingopine
  • HY-17363
    Dimethyl fumarate
    20+ Cited Publications

    		 Keap1-Nrf2 Reactive Oxygen Species HIV Autophagy Endogenous Metabolite Infection Neurological Disease Inflammation/Immunology Cancer
    Dimethyl fumarate (DMF) is an orally active and brain-penetrant Nrf2 activator and induces upregulation of antioxidant gene expression. Dimethyl fumarate induces necroptosis in colon cancer cells through GSH depletion/ROS increase/MAPKs activation pathway, and also induces cell autophagy. Dimethyl fumarate can be used for multiple sclerosis research .
    Dimethyl fumarate
  • HY-106376A
    L-Buthionine-(S,R)-sulfoximine
    5+ Cited Publications

    L-Buthionine sulfoximine; L-BSO

    		 Ferroptosis Cancer
    L-Buthionine-(S,R)-sulfoximine is a cell-permeable, potent, fast acting and irreversible inhibitor of g-glutamylcysteine synthetase and depletes cellular glutathione levels. The IC50 value of L-Buthionine-(S,R)-sulfoximine on melanoma, breast and ovarian tumor specimens are 1.9 μM, 8.6 μM, and 29 μM, respectively.
    L-Buthionine-(S,R)-sulfoximine
  • HY-P9923
    Benralizumab

    MEDI-563; BIW-8405

    		 Interleukin Related Apoptosis Inflammation/Immunology Cancer
    Benralizumab (MEDI-563) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma .
    Benralizumab
  • HY-P99730
    Mezagitamab

    TAK-079

    		 CD38 Cancer
    Mezagitamab (TAK-079) is a IgG1λ anti-CD38 monoclonal antibody. Mezagitamab depletes tumor cells expressing CD38 through antibody and complement dependent cytotoxicity. Mezagitamab has potential application in relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP) .
    Mezagitamab
  • HY-P9960
    Ocrelizumab

    Ocrevus

    		 CD20 Inflammation/Immunology
    Ocrelizumab is an anti-CD20 antibody that depletes circulating immature and mature B cells but spares CD20-negative plasma cells. The effector mechanisms of Ocrelizumab are complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. Ocrelizumab is the first monoclonal antibody for secondary primary progressive multiple sclerosis (PPMS) .
    Ocrelizumab
  • HY-90006
    5-Fluorouracil
    Maximum Cited Publications
    176 Publications Verification

    5-FU

    		 Nucleoside Antimetabolite/Analog HIV Apoptosis Endogenous Metabolite Cancer
    5-Fluorouracil (5-FU) is an analogue of uracil and a potent antitumor agent. 5-Fluorouracil affects pyrimidine synthesis by inhibiting thymidylate synthetase thus depleting intracellular dTTP pools. 5-Fluorouracil induces apoptosis and can be used as a chemical sensitizer . 5-Fluorouracil also inhibits HIV .
    5-Fluorouracil
  • HY-14374
    GPP78

    CAY10618

    		 NAMPT Autophagy Inflammation/Immunology Cancer
    GPP78 (CAY10618) is a potent Nampt inhibitor with an IC50 of 3.0 nM for nicotinamide adenine dinucleotide (NAD) depletion. GPP78 is cytotoxic to neuroblastoma cell line SH-SY5Y cells with an IC50 of 3.8 nM by inducing autophagy. GPP78 has anti-cancer and anti-inflammatory effects .
    GPP78
  • HY-132588
    Lumasiran

    ALN-G01

    		 Small Interfering RNA (siRNA) Metabolic Disease
    Lumasiran (ALN-G01), a siRNA product, reduces hepatic oxalate production by targeting glycolate oxidase. By silencing the gene encoding glycolate oxidase, Lumasiran depletes glycolate oxidase and thereby inhibits the synthesis of oxalate, which is the toxic metabolite that is directly associated with the clinical manifestations of Primary hyperoxaluria type 1 (PH1) .
    Lumasiran
  • HY-122753
    SLMP53-1

    		MDM-2/p53 Cancer
    SLMP53-1 is a wild-type and mutant p53 reactivator with promising antitumor activity. SLMP53-1 mediates the reprograming of glucose metabolism in cancer cells. SLMP53-1 depletes angiogenesis, decreasing endothelial cell tube formation and vascular endothelial growth factor (VEGF) expression levels .
    SLMP53-1
  • HY-A0184
    Remikiren

    Ro 42-5892; Ro 42-5892/001

    		 Renin Cardiovascular Disease
    Remikiren (Ro 42-5892) is an orally active and highly specific renin inhibitor. Remikiren specifically inhibits human reninand human plasma renin with IC50 values of 0.7 and 0.8 nM, respectively. Remikiren also reduces mean arterial blood pressure in sodium-depleted marmosets and squirrel monkeys. Remikiren can be used in study of hypertension .
    Remikiren
  • HY-155474
    Me4Phen

    		Apoptosis Cancer
    Me4Phen (compound 3) is an oxygen rhenium (V) complex that depletes mitochondrial membrane potential and upregulates intracellular reactive oxygen species (ROS), leading to endoplasmic reticulum stress-mediated necrosis of cancer cells. Me4Phen is highly lipophilic and effectively overcomes Cisplatin (HY-17394) resistance in a variety of cancer cells .
    Me4Phen
  • HY-Z0283
    Benzamide

    Benzenecarboxamide; Phenylamide

    		 Endogenous Metabolite PARP Others
    Benzamide (Benzenecarboxamide) is a potent poly(ADP-ribose) polymerase (PARP) inhibitor. Benzamide has protective activity against both glutamate- and methamphetamine (METH)-induced neurotoxicity in vitro. Benzamide can attenuate the METH-induced dopamine depletions and exhibits neuroprotective activity in mice, also has no acute effect on striatal dopamine metabolism and does not reduce body temperature .
    Benzamide
  • HY-134653
    5-Ph-IAA
    5+ Cited Publications

    		 Others Cancer
    5-Ph-IAA is a derivative of IAA. 5-Ph-IAA, a ligand, establishes the auxin-inducible degron 2 (AID2) system together with an OsTIR1 (F74G) mutant. AID2 induces rapid and efficient depletion of mAID-fused proteins to study protein function in living cells, causing tumor suppression .
    5-Ph-IAA
  • HY-132174
    CHIKV-IN-2

    		Flavivirus Dengue virus Dihydroorotate Dehydrogenase Infection
    CHIKV-IN-2 is a potent inhibitor against Chikungunya virus (CHIKV), with excellent cellular antiviral activity (EC90=270 nM) and improved liver microsomal stability. CHIKV-IN-2 shows inhibitory activity against a cellular target Dihydroorotate Dehydrogenase (DHODH), which interacts with various viruses and regulate their replication via depleting intracellular pyrimidine pools .
    CHIKV-IN-2
  • HY-106376C
    L-Buthionine-(S,R)-sulfoximine hydrochloride
    5+ Cited Publications

    L-Buthionine sulfoximine hydrochloride; L-BSO hydrochloride

    		 Ferroptosis Metabolic Disease Cancer
    L-Buthionine-(S,R)-sulfoximine hydrochloride is a cell-permeable, potent, fast acting, orally active and irreversible inhibitor of g-glutamylcysteine synthetase and depletes cellular glutathione levels. The IC50 value of L-Buthionine-(S,R)-sulfoximine on melanoma, breast and ovarian tumor specimens are 1.9 μM, 8.6 μM, and 29 μM, respectively .
    L-Buthionine-(S,R)-sulfoximine hydrochloride
  • HY-115832
    Ap44mSe

    		Others Cancer
    Ap44mSe is a selenosemicarbazone that effectively depletes cellular Fe, resulting in transferrin receptor-1 up-regulation, ferritin down-regulation, and increased expression of the potent metastasis suppressor, N-myc downstream regulated gene-1. Ap44mSe forms redox active Cu complexes that target the lysosome to induce lysosomal membrane permeabilization .
    Ap44mSe
  • HY-162135
    MAT2A-IN-14

    		Methionine Adenosyltransferase (MAT) Reactive Oxygen Species Cancer
    MAT2A-IN-14 (compound H3) is a MAT2A inhibitor, and generates reactive oxygen species after sonication to specifically degrade cellular MAT2A via rapid oxidative reactions. Combination of MAT2A-IN-14 and sonication induces 87% MAT2A depletion in human colon cancer cell .
    MAT2A-IN-14
  • HY-101461
    Methyl-β-cyclodextrin
    40+ Cited Publications

    Methyl-beta-cyclodextrin

    		 Biochemical Assay Reagents Cancer
    Methyl-β-cyclodextrin (Methyl-beta-cyclodextrin) is a cyclic heptasaccharide used to deliver hydrophobic agents based on its property of solubilizing non-polar substances. Methyl-β-cyclodextrin is also extensively used as a cholesterol-depleting reagent . Methyl-β-cyclodextrin strongly reduces clathrin-dependent endocytosis . Methyl-β-cyclodextrin blocks cell migrasome formation .
    Methyl-β-cyclodextrin
  • HY-155972A
    CRM1-IN-2

    		CRM1 Apoptosis Cancer
    CRM1-IN-2 (Compound KL2) is a noncovalent CRM1 inhibitor. CRM1-IN-2 localizes CRM1 in the nuclear periphery, depletes nuclear CRM1, and inhibits CRM1-mediated nuclear export. CRM1-IN-2 inhibits growth of colorectal cancer cells, and induces apoptosis .
    CRM1-IN-2
  • HY-42682
    D(+)-Galactosamine hydrochloride
    1 Publications Verification

    D-Galactosamine hydrochloride

    		 Others Inflammation/Immunology
    D(+)-Galactosamine (D-Galactosamine) hydrochloride, which is an established experimental toxin, primarily causes liver injury by the generation of free radicals and depletion of UTP nucleotides. D(+)-Galactosamine hydrochloride intoxication also induces renal dysfunction thus, renal failure is often associated with the end-stage of the liver damage. Lipopolysaccharide/D(+)-Galactosamine-induced acute liver injury is a known animal model of fulminant hepatic failure .
    D(+)-Galactosamine hydrochloride
  • HY-147816
    Anticancer agent 70

    		Mitochondrial Metabolism Cancer
    Anticancer agent 70 (Compound 21), an anticancer agent, exhibits remarkable cytotoxic activity against numerous human cancer cell lines. Anticancer agent 70 results in the G0/G1-cell cycle arrest with a concomitant increase in p53 and p21 protein levels. Anticancer agent 70 leads to ATP depletion and disruption of the mitochondrial membrane potential .
    Anticancer agent 70
  • HY-10211
    Tanespimycin
    30+ Cited Publications

    17-AAG; NSC 330507; CP 127374

    		 HSP Autophagy Mitophagy Bacterial Apoptosis Antibiotic Infection Cancer
    Tanespimycin (17-AAG) is a potent HSP90 inhibitor with an IC50 of 5 nM, having a 100-fold higher binding affinity for tumour cell derived HSP90 than normal cell derived HSP90 . Tanespimycin depletes cellular STK38/NDR1 and reduces STK38 kinase activity. Tanespimycin also downregulates the stk38 gene expression .
    Tanespimycin
  • HY-134539
    IMT1
    3 Publications Verification

    		 Oxidative Phosphorylation Mitochondrial Metabolism DNA/RNA Synthesis Metabolic Disease Cancer
    IMT1 is a first-in-class specific and noncompetitive human mitochondrial RNA polymerase (POLRMT) inhibitor. IMT1 causes a conformational change of POLRMT, which blocks substrate binding and transcription in a dose-dependent way in vitro. IMT1 reduces deoxynucleoside triphosphate levels and citric acid cycle intermediates, resulting in a marked depletion of cellular amino acid levels. IMT1 has the potential for mitochondrial transcription disorders related diseases .
    IMT1
  • HY-17363S1
    Dimethyl fumarate-d2

    		Autophagy HIV Keap1-Nrf2 Endogenous Metabolite Reactive Oxygen Species
    Dimethyl fumarate-d2 is the deuterium labeled Dimethyl fumarate[1]. Dimethyl fumarate (DMF) is an orally active and brain-penetrant Nrf2 activator and induces upregulation of antioxidant gene expression. Dimethyl fumarate induces necroptosis in colon cancer cells through GSH depletion/ROS increase/MAPKs activation pathway, and also induces cell autophagy. Dimethyl fumarate can be used for multiple sclerosis research[2][3].
    Dimethyl fumarate-d2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: